NCT05020678

URI: https://gptkb.org/entity/NCT05020678
GPTKB entity
Statements (29)
Predicate Object
gptkbp:instanceOf gptkb:clinical_trial
gptkbp:ageRange 18 Years and older
gptkbp:allocates Randomized
gptkbp:clinicalTrialPhase Phase 3
gptkbp:conditionStudied gptkb:COVID-19
gptkbp:enrollment 1433
https://www.w3.org/2000/01/rdf-schema#label NCT05020678
gptkbp:intervention gptkb:Molnupiravir
gptkbp:location gptkb:Argentina
gptkb:Brazil
gptkb:Colombia
gptkb:Mexico
gptkb:Russia
gptkb:South_Africa
gptkb:Ukraine
gptkb:United_States
gptkbp:mask Double
gptkbp:officialName A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Molnupiravir in Non-Hospitalized Adult Participants With COVID-19
gptkbp:primaryCompletionDate November 4, 2021
gptkbp:principalInvestigator Not specified
gptkbp:recognizedBy gptkb:NCT05020678
gptkbp:result Incidence of hospitalization or death through Day 29
gptkbp:sex All
gptkbp:sponsor gptkb:Merck_Sharp_&_Dohme_LLC
gptkbp:startDate August 5, 2021
gptkbp:status Completed
gptkbp:studyType Interventional
gptkbp:bfsParent gptkb:NKX019
gptkbp:bfsLayer 8